Adjuvant therapy in melanoma

Onkologie

Volumn 26, Issue 3, 2003, Pages 227-233

  Mohr, P ^a,c   Weichenthal, M ^b   Hauschild, A ^b  

^a Elbeklinikum Buxtehude ^*  (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c Am Krankenhaus 1   (Germany)

Author keywords

Adjuvant treatment; Immunotherapy; Interferon ; Interleukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; BCG VACCINE; BETA INTERFERON; BLEOMYCIN; CARMUSTINE; CISPLATIN; CORYNEBACTERIUM PARVUM VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; GANGLIOSIDE GM2; HYDROXYUREA; INTERLEUKIN 2; LEVAMISOLE; LOMUSTINE; MELACINE; MELPHALAN; PHOSPHORYL LIPID A; RETINOL; TAMOXIFEN; TRANSFER FACTOR; VINCRISTINE; VINDESINE; VISCUM ALBUM EXTRACT;

BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; DRUG TOXICITY; HUMAN; IMMUNIZATION; IMMUNOSTIMULATION; LOW DRUG DOSE; MELANOMA; MORBIDITY; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; MELANOMA; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0037666807     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071617     Document Type: Review

References (51)

1. Ballet CM, Maddox MA: The logic of adjunctive therapy in surgical patients with resectable cancer. South Med J 1978;71:951-955.
2. Goldie JH: Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 1987;14:1-7.
3. Barth A, Morton DL: The role of adjuvant therapy in melanoma management. Cancer 1995;75:726-734.
4. Hauschild A, Sterry W: Adjuvante Therapie des malignen Melanoms. Dtsch Med Wschr 1992;117:303-306.
5. Kirkwood JM, Agarwala SS: Adjuvant systemic therapy; in Balch CM, Houghton AN, Sober AJ, Soon Seng-jaw (eds): Cutaneous Melanoma. Quality Medical Publishing, St. Louis, 1998, pp 451-459.
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
7. Bast RC Jr, Zbar B, Borsos T, Rapp HJ: BCG and cancer. N Engl J Med 1974;290:1413-1420.
8. Eilber FR, Townsend CM Jr, Morton DL: Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am J Surg 1976;132:476-479.
9. Tilgen W: Therapie des malignen Melanoms: Derzeitiger Stand und Perspektiven; in Macher E, Kolde G, Bröcker EB (Hrsg): Jahrbuch der Dermatologie. Zülpich, Biermann, 1995, pp 123-150.
10. Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P: Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology 1996;193:105-109.
11. Meyskens FL, Kopecky K, Samson M, Hersh E, MacDonald J, Jaffe H, Crowley J, Coltman C: Recombinant human interferon gamma: Adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst 1990;82:1071.
12. Kleeberg U, Broecker EB, Chartier C: EORTC 18871 adjuvant trial in high risk melanoma patients IFNa vs IFNgamma vs Iscador vs observation. Eur J Cancer 1999;35(suppl 4):264.
13. Beiteke U, Ruppert P, Garbe C, Oxenfarth R, Kastl I, Türker T, Tronnier H, Frosch PJ: Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanen Interferon beta. Hautarzt 1993;44:365-371.
14. Richards JM: Sequential chemoimmunotherapy for metastatic melanoma. Semin Oncol 1991;18:91-95.
15. Kirkwood J M, Strawderman HM, Ernstoff SM, Smith TJ, Borden CE, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
16. Kirkwood JM, Ibrahim JG, Sondrak VK, Richards JR, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH: High- and low-dose interferon alpha-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
17. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
18. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430-1436.
19. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A: Effect on long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001;358:866-869.
20. Hancock BW, Wheatley K, Harrison G, Gore M: Aim high - adjuvant interferon in melanoma (high-risk), a United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. Proc Am Soc Clin Oncol 2001;20:349a.
21. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-1910.
22. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auboeck J, Fritsch P, Kerl H, Wolff K: Adjuvant interferon-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425-1429.
23. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R: Prospective randomized trial of interferon a2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma with-out clinically detectable node metastasis. J Clin Oncol 2003; in press.
24. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from phase III, randomised, double-blind, multicenter vaccina melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77.
25. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
26. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE: Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-2066.
27. Hersey P, Coates AS, McCarthy WH, Thomson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ: Adjuvant immunotherapy of patients with high risk melanoma using vaccinia viral lysates of melanoma. Results of a randomized trial. J Clin Oncol 2002;20:2067-2075.
28. Meisenberg BR, Ross M, Vredenburgh JJ, Jones R, Sphall EJ, Seigler HF, Coniglio DM, Wu K, Peters WP: Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst 1993;85:1080-1085.
29. Hill GJ 2nd, Moss SE, Golomb FM, Grage TB, Fletcher WS, Minton JP, Krementz ET: DTIC and combination therapy for melanoma, III: DTIC (NSC 45388) Surgical Adjuvant Study COG protocol 7040. Cancer 1981;34:2556-2562.
30. Retsas S, Quigley M, Pectasides D, Macrae K, Henry K: Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Cancer 1994;73:2119-2130.
31. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Filippo FD, Krementz ET, Ruiter D, Lejeune FJ: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treamtent of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-2912.
32. Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A: Interferon-a as adjuvant therapy for melanoma: A meta-analysis of the randomised trials. Proc ASCO 2001;20:349a.
33. Cascinelli N, Bufalino R, Morabito A, MacKie R: Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994;342:913-914.
34. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna B, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, MacKie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, Tomin R: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-916.
35. Kirkwood JM, Manola J, Ibrahim JG, Sondak VK, Ernstoff MS: Pooled analysis of four ECOG/Inter-group trials of high-dose interferon a-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma. Proc Am Soc Clin Oncol 2001;20:350a.
36. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-2783.
37. McMasters KM: The Sunbelt Melanoma Trial. Ann Surg Oncol 2001;8(suppl 9):41S-43S.
38. Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D, Ruiter DJ: The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Ann Surg Oncol 2001;8(suppl9):38S-40S.
39. Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, Smyth JF; Scottish Melanoma Group. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001 May 4;84:1146-1149.
40. Hancock BW, Wheatley K, Harrington G, Gore M: Aim high - adjuvant interferon in melanoma (high risk): A United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomized study on observation versus adjuvant low-dose extended duration interferon alpha2a in high-risk resected malignant melanoma. Proc ASCO 2001;20:349a.
41. Balch CM, Murray D, Presant C, Bartolucci AA: Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 1984;95:454-459.
42. Tranum BL, Dixon D, Quagliana J, Neidhart J, Balcerzak SP, Costanzi JH, Fabian CJ, Neilan B, Maloney T, O'Bryan RM: Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: A Southwest Oncology Group Study. Cancer Treat Rep 1987;71:643-644.
43. Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS: Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 1992;28:60-64.
44. Stables GI, Doherty VR, MacKie RM: Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. Br J Dermatol 1992;12:505-508.
45. Karakousis C, Blumenson L: Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. Eur J Cancer 1993;29A:1831-1835.
46. Pectasides D, Alevizakos N, Bafaloukos D, Tzonou A, Asimakopoulos G, Varthalitis I, Dimitriadis M, Athanassiou A: Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol 1994;17:55-59.
47. Miller LL, Spitler LE, Allen RE, Minor DR: A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988 15;61:1543-1549.
48. Creagan ET, Ingle JN, Schutt AJ, Schaid DJ: A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989;12:152-155.
49. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9:736-740.
50. Meyskens FL Jr, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD: Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2060-2065.
51. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM, Bartolucci AA: A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42.